Evidence map›Paper›PMID 36383605›Full record

ArticlePLoS biology2022

SARS-CoV-2 variant Alpha has a spike-dependent replication advantage over the ancestral B.1 strain in human cells with low ACE2 expression.

Daniela Niemeyer, Saskia Stenzel, Talitha Veith, Simon Schroeder, Kirstin Friedmann, Friderike Weege, Jakob Trimpert, Julian Heinze, Anja Richter, Jenny Jansen and 33 more

Open access · goldAbstract read
In one paragraph

Article in PLoS biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Polysialosides Outperform Sulfated Analogs for Binding with SARS-CoV-2.Small (Weinheim an der Bergstrasse, Germany) · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors at 11 institutions in 3 countries.

Daniela NiemeyerInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Saskia StenzelInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Talitha VeithInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Simon SchroederInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Kirstin FriedmannInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Friderike WeegeInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Jakob TrimpertInstitut für Virologie, Freie Universität Berlin, Berlin, Germany.
Julian HeinzeInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Anja RichterInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Jenny JansenInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Jackson EmanuelInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Julia KazmierskiInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Fabian PottInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Lara M JeworowskiInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Ruth OlmerLeibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Department of Cardiothoracic, Transplantation and Vascular Surgery, REBIRTH - Center for Translational Regenerative Medicine, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover Medical School, Hannover, Germany.
Mark-Christian JaboreckLeibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Department of Cardiothoracic, Transplantation and Vascular Surgery, REBIRTH - Center for Translational Regenerative Medicine, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover Medical School, Hannover, Germany.
Beate TennerInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Jan PapiesInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Felix WalperInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Marie L SchmidtInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Nicolas HeinemannInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Elisabeth Möncke-BuchnerInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Morris BaumgardtDepartment of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Karen HoffmannDepartment of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Marek WideraInstitute for Medical Virology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Tran Thi Nhu ThaoInstitute of Virology and Immunology, Bern, Switzerland.
Anita BalázsDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Jessica SchulzeUnit 17 "Influenza and other Respiratory Viruses", Robert Koch Institute, Berlin, Germany.
Christin MacheUnit 17 "Influenza and other Respiratory Viruses", Robert Koch Institute, Berlin, Germany.
Terry C JonesInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Markus MorkelInstitute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt - Universität zu Berlin, Berlin, Germany.
Sandra CiesekInstitute for Medical Virology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Leif G HanitschInstitute of Medical Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
Marcus A MallInstitut für Virologie, Freie Universität Berlin, Berlin, Germany.
Andreas C HockeDepartment of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Volker ThielInstitute of Virology and Immunology, Bern, Switzerland.
Klaus OsterriederBerlin Institute of Health, Berlin, Germany.
Thorsten WolffUnit 17 "Influenza and other Respiratory Viruses", Robert Koch Institute, Berlin, Germany.
Ulrich MartinLeibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Department of Cardiothoracic, Transplantation and Vascular Surgery, REBIRTH - Center for Translational Regenerative Medicine, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover Medical School, Hannover, Germany.
Victor M CormanInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Marcel A MüllerInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Christine GoffinetInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-3959-004X
Christian DrostenInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0001-7923-0519
Charité - Universitätsmedizin Berlin · DEBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEGerman Center for Infection Research · DEMedizinische Hochschule Hannover · DERobert Koch Institute · DEGoethe University Frankfurt · DEHumboldt-Universität zu Berlin · DEVivantes Klinikum · DECity University of Hong Kong · HKFreie Universität Berlin · DEGerman Center for Lung Research · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidemiological data demonstrate that Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) Alpha and Delta are more transmissible, infectious, and pathogenic than previous variants. Phenotypic properties of VOC remain understudied. Here, we provide an extensive functional study of VOC Alpha replication and cell entry phenotypes assisted by reverse genetics, mutational mapping of spike in lentiviral pseudotypes, viral and cellular gene expression studies, and infectivity stability assays in an enhanced range of cell and epithelial culture models. In almost all models, VOC Alpha spread less or equally efficiently as ancestral (B.1) SARS-CoV-2. B.1. and VOC Alpha shared similar susceptibility to serum neutralization. Despite increased relative abundance of specific sgRNAs in the context of VOC Alpha infection, immune gene expression in infected cells did not differ between VOC Alpha and B.1. However, inferior spreading and entry efficiencies of VOC Alpha corresponded to lower abundance of proteolytically cleaved spike products presumably linked to the T716I mutation. In addition, we identified a bronchial cell line, NCI-H1299, which supported 24-fold increased growth of VOC Alpha and is to our knowledge the only cell line to recapitulate the fitness advantage of VOC Alpha compared to B.1. Interestingly, also VOC Delta showed a strong (595-fold) fitness advantage over B.1 in these cells. Comparative analysis of chimeric viruses expressing VOC Alpha spike in the backbone of B.1, and vice versa, showed that the specific replication phenotype of VOC Alpha in NCI-H1299 cells is largely determined by its spike protein. Despite undetectable ACE2 protein expression in NCI-H1299 cells, CRISPR/Cas9 knock-out and antibody-mediated blocking experiments revealed that multicycle spread of B.1 and VOC Alpha required ACE2 expression. Interestingly, entry of VOC Alpha, as opposed to B.1 virions, was largely unaffected by treatment with exogenous trypsin or saliva prior to infection, suggesting enhanced resistance of VOC Alpha spike to premature proteolytic cleavage in the extracellular environment of the human respiratory tract. This property may result in delayed degradation of VOC Alpha particle infectivity in conditions typical of mucosal fluids of the upper respiratory tract that may be recapitulated in NCI-H1299 cells closer than in highly ACE2-expressing cell lines and models. Our study highlights the importance of cell model evaluation and comparison for in-depth characterization of virus variant-specific phenotypes and uncovers a fine-tuned interrelationship between VOC Alpha- and host cell-specific determinants that may underlie the increased and prolonged virus shedding detected in patients infected with VOC Alpha.

Indexed as

COVID-19SARS-CoV-2Angiotensin-Converting Enzyme 2Antibodies, BlockingHumansVirus SheddingAngiotensin-Converting Enzyme 2Antibodies, Blocking

Identifiers

PMID36383605
PMCPMC9710838
OpenAlexW4309134924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.